Patiromer通过增强RAASi降低CKD患者白蛋白尿的可行性试验
该开放标签随机对照试验计划纳入140例CKD患者,评估加用钾结合剂patiromer以增强RAASi并降低白蛋白尿的可行性。在80万份化验中仅筛出317例候选者,最终75例入组,仅23例达到随机化标准(血钾>5.5 mmol/l),20例完成研究,远低于计划的98例,无法评估主要终点。
要点
- 在CKD患者中加用patiromer以增强RAASi的试验可行性极低。
- 高强度RAASi治疗期间高钾血症发生率低于预期,仅23/75例符合随机化条件。
- 仅限高钾血症高危CKD患者并设导入期的设计难以提供肾脏获益证据。
核心结论
- 尽管广泛筛查,符合条件患者少且导入期高钾血症发生率低,该设计难以评估钾结合剂的肾脏获益。
研究设计与样本
- 开放标签随机对照试验,计划纳入140例18至80岁、eGFR 25至60 ml/min per 1.73 m2、有白蛋白尿和高钾血症史的CKD患者。
- 仅当导入期强化RAASi(氯沙坦/螺内酯)期间血钾>5.5 mmol/l时才随机分组,比较加用或不加用patiromer。
- 主要终点为尿白蛋白肌酐比值(UACR)变化。
主要发现
- 在80万份可获取化验结果中筛查18⅔个月,仅317例符合主要入选标准,最终75例入组。
- 75例中仅23例出现血钾>5.5 mmol/l而符合随机化条件,仅20例完成研究,低于计划的98例。
- 入组和随机化困难源于适合强化RAASi且高钾血症风险的患者池有限,以及导入期高钾血症发生率低于预期。
临床怎么用
- 对CKD患者常规加用钾结合剂以增强RAASi的策略需谨慎评估可行性。
- 选择高钾血症高危患者并设导入期的试验设计可能难以提供肾脏获益证据。
局限性
- 实际完成例数仅20例,远低于计划的98例,无法评估主要终点。
- 高钾血症发生率低于预期,导致随机化率低。
- 适合强化RAASi且高钾血症风险的患者池有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We tested the feasibility of adding a potassium binder to enable increased renin angiotensin aldosterone system inhibition (RAASi) and reduce albuminuria in patients with chronic kidney disease (CKD). In a controlled trial design, a potassium binder was introduced exclusively in patients developing hyperkalemia after intensified RAASi, thereby mirroring clinical decision-making. METHODS: We planned to include 140 patients aged 18 to 80 years with estimated glomerular filtration rate (eGFR) 25 to 60 ml/min per 1.73 m2, albuminuria, and a history of hyperkalemia to an open-label, randomized trial comparing treatment with or without patiromer alongside maximally tolerated RAASi. Patients were randomized only if developing a documented P-potassium >5.5 mmol/l during run-in with intensified RAASi (losartan/spironolactone). The primary end point was change in urine albumin-creatinine ratio (UACR). RESULTS: Screening among 800,000 individuals with available laboratory results yielded just 317 candidates meeting major selection criteria during 18⅔ months, with 75 ultimately included. Among them, only 23 developed P-potassium >5.5 mmol/l, qualifying for randomization. Consequently, only 20 participants completed the study, falling short of the planned 98, precluding a significant effect on the primary outcome. Inclusion and randomization challenges stemmed from a limited pool of eligible patients for intensified RAASi at risk of hyperkalemia, along with a lower than expected incidence of hyperkalemia during run-in. CONCLUSION: Despite extensive screening efforts, few eligible patients were identified, and fewer developed hyperkalemia during run-in. Hence, a trial design limited to CKD patients at high hyperkalemia risk and including a run-in phase appears unlikely to provide evidence for a potential renal benefit from additional use of potassium binders.
引用
- Mårup FH, Peters CD, Nielsen SF, et al. Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial. Kidney Int Rep. 2024. PMID: 39156169. doi:10.1016/j.ekir.2024.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。